Search results for "nuclear medicine and imaging"

showing 10 items of 2516 documents

Somatosensory Brain Function and Gray Matter Regional Volumes Differ According to Exercise History : Evidence from Monozygotic Twins

2017

Associations between long-term physical activity and cortical function and brain structure are poorly known. Our aim was to assess whether brain functional and/or structural modulation associated with long-term physical activity is detectable using a discordant monozygotic male twin pair design. Nine monozygotic male twin pairs were carefully selected for an intrapair difference in their leisure-time physical activity of at least three years duration (mean age 34 ± 1 years). We registered somatosensory mismatch response (SMMR) in EEG to electrical stimulation of fingers and whole brain MR images. We obtained exercise history and measured physical fitness and body composition. Equivalent ele…

0301 basic medicineMaleFITNESSMismatch negativityphysical activityMismatch negativityElectroencephalographycomputer.software_genreSomatosensory systemSuperior temporal gyrus0302 clinical medicineVoxelBrain structureGENERATORSTwin researchGray MatterRadiological and Ultrasound Technologymedicine.diagnostic_testOrgan SizeMagnetic Resonance Imaging3142 Public health care science environmental and occupational healthmedicine.anatomical_structureNeurologyEXCITABILITYHEALTHAnatomyPsychologyAdultsomatosensory cortexMISMATCH NEGATIVITY MMNPOTENTIALS03 medical and health sciencesTIME PHYSICAL-ACTIVITYmedicineBrain electrophysiologyHumansRadiology Nuclear Medicine and imagingMODULATIONExercisekaksostutkimusbrain electrophysiologyPostcentral gyrusPhysical activitybrain structureTwins MonozygoticMedial frontal gyrusTwin studySomatosensory cortex030104 developmental biologyDISCRIMINATIONNeurology (clinical)poikkeavuusnegatiivisuuscomputerNeuroscience030217 neurology & neurosurgeryRESPONSES
researchProduct

Hereditary prostate cancer – Primetime for genetic testing?

2019

Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa attributable to high-risk hereditary factors has been estimated to 5-15%. Recent landmark discoveries in PCa genetics led to the identification of germline mutations/alterations (eg. BRCA1, BRCA2, ATM or HOXB13), single nucleotide polymorphisms or copy number variations associated with PCa incidence and progression. However, offering germline testing to men with an assumed hereditary component is currently controversial. In the present review article, we provide an overview about the epidemiology and the genetic basis of PCa predisposition and critically discuss the significance and consequence in the cli…

0301 basic medicineMaleGenetic testingDNA Copy Number VariationsGenome-wide association studySingle-nucleotide polymorphismDiseaseBioinformaticsPolymorphism Single Nucleotide03 medical and health sciencesProstate cancer0302 clinical medicineGermline mutationMedicineHumansRadiology Nuclear Medicine and imagingGenetic Predisposition to DiseaseCopy-number variationGenetic TestingPrecision MedicineGenetic testingBRCA2 ProteinHomeodomain ProteinsClinical Trials as TopicProstate cancermedicine.diagnostic_testbusiness.industryBRCA1 ProteinCancerProstatic NeoplasmsPrecision oncologyGeneral Medicinemedicine.diseaseCheckpoint Kinase 2030104 developmental biologyHereditaryOncology030220 oncology & carcinogenesisMutationbusiness
researchProduct

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

2020

Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10% of EGFR mutations, harboring heterogeneous molecular alterations within exons 18-21 with clinically variable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced Non-Small Cell Lung Cancer (NSCLC) patients. In addition, with the introduction of different NGS gene approach an improvement of EGFR mutations detection was reported. Today, no specific studies have prospectively evaluated uncommon sensitizing mutations in detail and no firm standard of care has been established in the first-line setting. The aim of this comprehensive review is to critically consider the clinical role of uncommon EGF…

0301 basic medicineMaleLung NeoplasmsPrognosiEGFRProtein Kinase Inhibitormedicine.disease_causeNSCLC03 medical and health sciencesExonErbB Receptors0302 clinical medicineCarcinoma Non-Small-Cell LungmedicineCarcinomaHumansRadiology Nuclear Medicine and imagingEpidermal growth factor receptorErbB ReceptorLung cancerGeneProtein Kinase InhibitorsRegulation of gene expressionMutationbiologybusiness.industryGeneral Medicinemedicine.diseasePrognosisTKIUncommon mutationErbB ReceptorsGene Expression Regulation NeoplasticLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisNGSMutationCancer researchbiology.proteinSystematic reviewFemalebusinessHuman
researchProduct

Review of imaging network activities in developing rodent cerebral cortex in vivo

2016

The combination of voltage-sensitive dye imaging (VSDI) with multielectrode array (MEA) recordings in the rodent cerebral cortex in vivo allows the simultaneous analysis of large-scale network interactions and electrophysiological single-unit recordings. Using this approach, distinct patterns of spontaneous and sensory-evoked activity can be recorded in the primary somatosensory (S1) and motor cortex (M1) of newborn rats. Already at the day of birth, gamma oscillations and spindle bursts in the barrel cortex synchronize the activity of a local columnar ensemble, thereby generating an early topographic representation of the sensory periphery. During the first postnatal week, both cortical ac…

0301 basic medicineNeocortexRadiological and Ultrasound TechnologyNeuroscience (miscellaneous)Sensory systemMultielectrode arrayBiologyBarrel cortexSomatosensory system03 medical and health sciencesElectrophysiology030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCerebral cortexmedicineRadiology Nuclear Medicine and imagingPioneers in Neurophotonics: Special Section Honoring Professor Amiram GrinvaldNeuroscience030217 neurology & neurosurgeryMotor cortexNeurophotonics
researchProduct

Épidémiologie du cancer du pancréas

2018

Actually, pancreatic cancer is a major challenge in digestive oncology. Its prognosis remains very poor with a five-year net survival less than 10%. Although if pancreatic cancer incidence was low, data from French digestive cancer registries show a dramatic increase in recent years, more marked in women (annual variation of +3.6% between 1982 and 2012) than in men (+2.3%). The currently recognized risk factors like tobacco or obesity cannot explain this evolving epidemiology. Moreover, progress in understanding pancreatic carcinogenesis is still insufficient. Except for familial aggregation, systematic screening couldn't be proposed.

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Family aggregationHematologyGeneral Medicinemedicine.diseaseObesity03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinePancreatic cancerEpidemiologymedicineRadiology Nuclear Medicine and imagingPancreatic carcinogenesisAnnual variationbusinessNet SurvivalBulletin du Cancer
researchProduct

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer

2018

The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy represented a milestone in the treatment of lung cancer over the last years. Tumor genotyping has been incorporated into therapeutic decision making of advanced non-small cell lung cancer (NSCLC) since has become clear that individuals with actionable molecular alterations receiving a matched targeted agent certainly live longer and better. The recent understanding of biological mechanisms underlying cancer immune evasion has allowed the development of a new class of immunomodulatory agents which are able to reactivate host immune-response, offering the potential for long-term disease control …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtycombinationsoncogene driversmedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Treatment of lung cancerReview Articleoncogene driverTargeted therapyTargeted therapy03 medical and health sciencesInternal medicinemedicineRadiology Nuclear Medicine and imagingLung cancercombinationOncogenebusiness.industryCancerImmunotherapymedicine.diseaseClinical trialnon-small cell lung cancer (NSCLC)030104 developmental biologyOncologyimmunotherapybusiness
researchProduct

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

2017

Purpose To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. Methods and Materials The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence…

0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentDocetaxelMastectomy Segmentallaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsAnthracyclinesMastectomyRadiationHazard ratioCarcinoma Ductal BreastMiddle Agedmedicine.anatomical_structureEditorialOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms03 medical and health sciencesYoung AdultBreast cancerInternal medicinemedicineConfidence IntervalsHumansRadiology Nuclear Medicine and imagingCyclophosphamideAgedNeoplasm StagingPostoperative Carebusiness.industryCancermedicine.diseaseClinical trialAxilla030104 developmental biologyDoxorubicinAxillaLymph Node ExcisionLymph NodesbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

2017

Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred and eighty patients with BRAF-mutant metastatic melanoma who had progressed on treatment with single-agent BRAFi from February 2010 to April 2015 were included in a retrospective data analysis focused on patterns of progression, treatment beyond progression (TBP) and subsequent treatments after BRAFi therapy. Analysis revealed that 51.1% of patients progressed with both new and existing metastas…

0301 basic medicineOncologyMaleCancer ResearchSkin NeoplasmsBRAF inhibitorProgrammed Cell Death 1 ReceptorMedizinKaplan-Meier Estimate0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsVemurafenibMelanomaOriginal ResearchAged 80 and overTreatment optionsMiddle AgedMAP Kinase Kinase KinasesPrognosisProgression-Free SurvivalOncology030220 oncology & carcinogenesisDisease ProgressionvemurafenibFemalemedicine.drugmetastatic melanomaBRAF inhibitorAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyMetastatic melanomaRetrospective data03 medical and health sciencesYoung AdultInternal medicinetreatment beyond progressionmedicineOverall survivalHumansRadiology Nuclear Medicine and imagingIn patientdabrafenibProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedRetrospective Studiesbusiness.industryClinical Cancer ResearchDabrafenib030104 developmental biologyBRAF mutationDrug Resistance NeoplasmMutationprogressionbusinessFollow-Up StudiesCancer Medicine
researchProduct

Prognosis and cure of long-term cancer survivors: A population-based estimation.

2019

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.…

0301 basic medicineOncologyMaleCancer ResearchTime FactorsSettore MED/42 - Igiene Generale E Applicata0302 clinical medicineCancer SurvivorsProstateNeoplasmsThyroid cancerOriginal Researcheducation.field_of_studyRelative survivalMortality rateMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosispopulation-based cancer registriemedicine.anatomical_structureOncologyItaly030220 oncology & carcinogenesiscancer cure Italy population-based cancer registries prevalence survivalFemaleCancer PreventionAdultmedicine.medical_specialtypopulation-based cancer registriesAdolescentPopulationprevalenceSocio-culturalelcsh:RC254-282survival03 medical and health sciencesYoung AdultLife ExpectancyInternal medicinemedicinepopulation‐based cancer registriesHumansRadiology Nuclear Medicine and imagingcancer cureeducationAgedEstimationbusiness.industryCancerModels Theoreticalmedicine.disease030104 developmental biologyLife expectancycancer cure; Italy; population-based cancer registries; prevalence; survivalbusinessCancer medicine
researchProduct

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy

2019

[EN] Somatic mutation analysis and evaluation of microsatellite instability (MSI) have become mandatory for selecting personalized therapy strategies for advanced colorectal cancer and are not available as routine methods in Paraguay. The aims of this study were to analyze the molecular profile as well as the microsatellite status in a series of advanced colorectal patients from two public hospitals from Paraguay, to introduce these methodologies in the routine practice to guide the therapeutic decisions. Thirty-six patients diagnosed with advanced colorectal cancer from two referent public hospitals from Paraguay were recruited from May 2017 to February 2018. Sequenom Mass spectrometry, On…

0301 basic medicineOncologyMaleCancer Researchmutational profileColorectal cancerDNA Mutational AnalysisKaplan-Meier Estimate0302 clinical medicineOriginal ResearchCancer BiologyPrecision medicineHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistryOncology030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityDisease SusceptibilityColorectal NeoplasmsAdultmedicine.medical_specialtyprecision medicinecolorectal cancerlcsh:RC254-28203 medical and health sciencesYoung AdultInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industryMicrosatellite instabilityOncocartaPrecision medicinemedicine.diseaseColorectal cancerMutational profile030104 developmental biologyMutationMicrosatellite instabilityMolecular ProfileNeoplasm GradingbusinessLENGUAJES Y SISTEMAS INFORMATICOSMicrosatellite Repeats
researchProduct